evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches.

The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile.

Who Took Part

According to the abstract, 1840 patients were involved.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

Eligible participants were men or women aged 55-85 years with mild cognitive impairment or mild dementia due to AD with confirmed amyloid abnormalities (assessed by positron emission tomography or cerebrospinal fluid [CSF] analysis).

After a maximum 12-week screening phase, an anticipated 1840 patients in each trial are randomized (1:1) to semaglutide or placebo for 156 weeks (104-week main treatment phase and 52-week extension).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Semaglutide, giving a reference point.

The timeline in the abstract includes 156 weeks.

The primary endpoint is the semaglutide-placebo difference on change from baseline to week 104 in the Clinical Dementia Rating - Sum of Boxes score.

Analyses of plasma biomarkers, collected from all participants, and a CSF sub-study (planned n = 210) will explore semaglutide effects on AD biomarkers and neuroinflammation.

What Was Measured

The subject headings attached to it are Glucagon-Like Peptides, Alzheimer Disease and Semaglutide.

Author keywords: Alzheimer’s disease, Clinical trial, Design, Neuroinflammation, evoke and evoke+.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 1840 patients over 156 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Alzheimer's research & therapy), a journal based in England.

More context: the Semaglutide compound page, all human trials.